Despite achieving statistically signficant improvement in progression-free survival in North American and European patients, Summit’s drug ivonescimab fell short of the other Phase 3 goal measuring overall survival. It’s the first Phase 3 readout for an emerging class of bispecific antibodies that treat cancer by blocking two targets, PD-1 and VEGF.
The post Summit Lung Cancer Drug Falls Short on Key Survival Goal in Global Study, Putting FDA Approval in Doubt appeared first on MedCity News.
